TY  - GEN
AU  - Saab,Sammy
AU  - Parisé,Hélène
AU  - Virabhak,Suchin
AU  - Wang,Alice
AU  - Marx,Steven E
AU  - Sanchez Gonzalez,Yuri
AU  - Misurski,Derek
AU  - Johnson,Scott
TI  - Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US
SN  - 1941-837X
PY  - 2017///0626
KW  - 2-Naphthylamine
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Anilides
KW  - economics
KW  - Antiviral Agents
KW  - administration & dosage
KW  - Benzimidazoles
KW  - Carbamates
KW  - Carcinoma, Hepatocellular
KW  - Cost-Benefit Analysis
KW  - Cyclopropanes
KW  - Drug Therapy, Combination
KW  - Female
KW  - Fibrosis
KW  - Fluorenes
KW  - Genotype
KW  - Hepacivirus
KW  - genetics
KW  - Hepatitis C, Chronic
KW  - drug therapy
KW  - Humans
KW  - Lactams, Macrocyclic
KW  - Liver Neoplasms
KW  - Macrocyclic Compounds
KW  - Male
KW  - Markov Chains
KW  - Middle Aged
KW  - Models, Econometric
KW  - Proline
KW  - analogs & derivatives
KW  - Quality-Adjusted Life Years
KW  - Ribavirin
KW  - Simeprevir
KW  - Sofosbuvir
KW  - Sulfonamides
KW  - Uracil
KW  - Valine
N1  - Publication Type: Journal Article
UR  - https://doi.org/10.1080/13696998.2016.1176030
ER  -